Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Gastroenterol Nurs ; 39(4): 325, 2016.
Article in English | MEDLINE | ID: mdl-27467063
2.
Gastroenterol Nurs ; 39(3): 244, 2016.
Article in English | MEDLINE | ID: mdl-27258468

Subject(s)
Death
3.
Liver Transpl ; 22(3): 281-6, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26335142

ABSTRACT

Combination antiviral therapy involving sofosbuvir (SOF) and simeprevir (SIM) is a treatment option in patients with genotype 1 chronic hepatitis C; however, the safety of this regimen in patients with decompensated cirrhosis is not established. Data from a combined treatment cohort of 2 large hepatology referral centers were evaluated to assess for safety and efficacy of SIM plus SOF with or without ribavirin (RBV) in patients with Child B or C cirrhosis. All (n = 42) patients included in the analysis had Child B (n = 35) or C (n = 7) cirrhosis and received 400 mg daily of SOF plus 150 mg daily of SIM, with (n = 7) or without (n = 35) RBV, for 12 weeks. Of the 42 patients in this cohort, 31 (74%) were male, 22 (52%) had failed prior treatments, and 28 (67%) were genotype 1a. Prior decompensating events included encephalopathy (57%), fluid overload (88%), or variceal hemorrhage (24%). Median Model for End-Stage Liver Disease score was 12 (range, 6-25). Treatment was well tolerated overall with more than one-half (57%) reporting no adverse events. In those reporting adverse events, the most common were fatigue (n = 6), insomnia (n = 4), headache (n = 5), nausea (n = 4), and grade 1 rash (n = 1). One patient developed chemical pancreatitis that did not require treatment discontinuation. Three of 7 patients who received RBV developed anemia, with 2 requiring blood transfusions and 1 requiring a dose reduction. No episodes of decompensation requiring hospitalization or deaths occurred on treatment. Of 42 patients, 38 (90%) patients had negative viral load at end of treatment (EOT), and 31 of 42 patients (74%) achieved sustained virological response 12 weeks after EOT; 10 of 10 patients (100%) with HCV genotype 1b achieved sustained virological response for 12 weeks (SVR12). In conclusion, SOF plus SIM was very well tolerated in patients with advanced Child B/C decompensated cirrhosis. Overall, 74% of patients achieved SVR12; 100% of patients with genotype 1b decompensated cirrhosis achieved SVR12.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Hepatitis Viruses/drug effects , Liver Cirrhosis/drug therapy , Ribavirin/therapeutic use , Simeprevir/therapeutic use , Sofosbuvir/therapeutic use , Adult , Aged , Antiviral Agents/adverse effects , Drug Therapy, Combination , Female , Genotype , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/diagnosis , Hepatitis Viruses/genetics , Humans , Liver Cirrhosis/diagnosis , Liver Cirrhosis/virology , Male , Middle Aged , Prospective Studies , Ribavirin/adverse effects , Simeprevir/adverse effects , Sofosbuvir/adverse effects , Texas , Time Factors , Treatment Outcome
4.
Gastroenterol Nurs ; 35(3): 215-24, 2012.
Article in English | MEDLINE | ID: mdl-22647802

ABSTRACT

End-stage liver disease (ESLD) is a leading cause of digestive disease deaths in the United States and continues to increase exponentially every year. Best practice does not currently recognize or utilize a clinic practice model for ESLD management. Advanced practice registered nurses (APRNs) can impact ESLD disease management by implementing an outpatient clinic care model to focus on treatment compliance, patient education, improvement of patient outcomes, and reduction in hospital admission rates for ESLD patients. A review of 15 research articles was completed to determine the impact APRNs can make on chronic care of ESLD patients. Results from the review support APRN analysis, assessment, diagnosis, treatment, intervention, and evaluation of ESLD patients. The literature reviewed also demonstrates that ESLD patients have improved symptom management when maintained in an outpatient setting, allowing for decreased hospital and insurance expenditures. Following evaluation of the evidence, it was concluded that an APRN-led ESLD clinic merits further study.


Subject(s)
Advanced Practice Nursing/organization & administration , Leadership , Liver Failure/nursing , Nurse Practitioners/organization & administration , Ambulatory Care/organization & administration , Ambulatory Care Facilities/organization & administration , Female , Humans , Long-Term Care , Male , Nurse's Role , Organizational Innovation , Outcome Assessment, Health Care , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...